Keep up to date, join us on...
According to a recent study, EndoBarrier Therapy is a safe and effective way of controlling type 2 diabetes and obesity.
The study conducted by Professor Reginald V Lord, from Sydney’s St. Vincent’s Clinic and Macquarie Hospitals involved the retrospective analysis of the first 100 Australian patients to receive the groundbreaking therapy and the results showed a significant reduction in, and in some cases an elimination of, insulin therapy by patients with type 2 diabetes and obesity.
“While based on a small number of patients, these findings show that EndoBarrier Therapy has a real, immediate impact on glycaemic levels,” said Professor Reginald V Lord. “We are pleased that EndoBarrier Therapy offers the opportunity for patients to reduce their reliance on insulin, which is often viewed as a last resort treatment for diabetes.”
Of the 100 patients analysed, only 11 required the use of insulin to manage their type 2 diabetes prior to receiving EndoBarrier Therapy. The analysis revealed that six (or 54 per cent) of these 11 insulin reliant patients with type 2 diabetes were able to completely cease the use of insulin therapy post surgery. The remaining five insulin-treated patients, whilst not able to stop insulin treatment completely, were able to decrease the frequency and dosage of their insulin therapy.
The analysis also demonstrated that EndoBarrier Therapy is also an effective weight loss surgery option as Professor Reginald V Lord’s study showed patients achieved a median weight loss of 11.1kg post therapy.
The EndoBarrier is a thin flexible tube that is placed inside the intestine to create a physical barrier between the intestinal wall and the food consumed. The liner remains there for up to 12 months; after which it is removed. This surgical procedure has been available in Australia since 2010.